NeuroSense Therapeutics has appealed Nasdaq's delisting decision, keeping its shares trading while awaiting a panel hearing on November 10, 2026. The company has regained compliance with Nasdaq's minimum bid price but must address the market value requirement. Near-term milestones include submitting a New Drug Application to Health Canada by December 2026 and a decision on non-dilutive funding for its Phase 3 PARAGON trial expected in early 2027. These developments are crucial for NeuroSense's lead drug PrimeC, aimed at treating ALS and other neurodegenerative diseases.
NeuroSense Therapeutics appears alongside a health sector where 76 of 128 US stocks rose today. For readers following health stocks, here is Pluang's market snapshot as of Oct 13, 2026 18:43 WIB: Neurocrine Biosciences Inc (NBIX) traded at USD 139.00 with a 1-day change of -1.68% and a typical hold time on Pluang of 24 days, showing 100% sell order activity. AstraZeneca plc (AZN) was priced at USD 160.93, up 1.64%, with 80% sell and 20% buy activity, while Sanofi SA (SNY) rose 1.59% to USD 40.37, with 74% buy orders and a typical hold time of 94 days.
Existing-home sales in the U.S. increased by 1.5% month-over-month in September but declined 2.2% compared to the previous year, according to the National Association of Realtors. Sales rose in the South and West regions but fell in the Northeast and...
Columbus Marketing Experts, a digital marketing agency in Hilliard, Ohio, is expanding its local SEO services across Columbus to help service businesses improve their visibility on Google Search and Google Maps. The expansion aims to enhance local di...
Schrödinger's stock fell 5.02% to $25.91 despite co-founding Tectora, a new biopharma venture with $55 million funding targeting immune and inflammatory treatments. The company, known for its molecular modeling software, holds a market value of about...
Johnson & Johnson reported third-quarter 2026 earnings per share of $2.59, surpassing analyst estimates of $2.52, with total revenue of $25.40 billion slightly above expectations. The company saw robust growth in its pharmaceutical segment, which off...
Nvidia CEO Jensen Huang has reaffirmed his forecast that global spending on AI infrastructure will grow significantly, reaching between $3 trillion and $4 trillion by 2030. This projection highlights the massive potential and ongoing investment in AI...
